23 Oct 2015

Lantus (Insuline glargine) - France

ATC: A10AE
ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
INSULINS AND ANALOGUES FOR INJECTION, LONG-ACTING
Lantus

Generic Matches for Insuline glargine (2)
Toujeo
Abasaglar

Last Updated on 23 Oct 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Lantus Indication

Traitement du diabète sucré de l’adulte, de l’adolescent et de l’enfant à partir de 2 ans.

 

Lantus Generic Name

Insuline glargine

Type

POM

Summary Product Characteristics (SPCs) Links
Résumé des Caractéristiques du Produit - Lantus (external site)

Related Learning Zones

Type 1 Childhood Diabetes CME

Type 1 Childhood Diabetes CME

In this EACCME-accredited online CME activity Individual Patient Management in Type 1 Childhood Diabetes, healthcare professionals will learn how to assess the psychosocial wellbeing of young patients with type 1 diabetes. 

Upon successful completion of this activity, healthcare professionals (such as endocrinologists, paediatricians, paediatric endocrinologists, diabetes specialists, specialist nurses, primary care physicians) will be awarded 1 European CME credit (ECMEC).

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Selected content related to Lantus (Insuline glargine)

Clinical Trials

News

Guidelines

Lantus Marketing Information

Lantus Generic Name
Insuline glargine
Marketing Company
Sanofi-Aventis Deutschland GmbH
Drug Type
POM
Date of Issue, Marketing Authority

09/06/2000

Médicaments utilisés en Endocrinologie et Diabète

Back to top